Asterias Biotherapeutics (AST) Receiving Somewhat Favorable News Coverage, Study Shows
News coverage about Asterias Biotherapeutics (NYSE:AST) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Asterias Biotherapeutics (NYSE:AST) traded up 1.54% on Friday, hitting $3.30. 48,750 shares of the company traded hands. The stock’s 50-day moving average is $3.49 and its 200 day moving average is $3.50. Asterias Biotherapeutics has a 12 month low of $2.54 and a 12 month high of $5.80. The stock’s market cap is $162.57 million.
Several research firms have issued reports on AST. HC Wainwright set a $12.00 price target on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research downgraded shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.